comparemela.com
Home
Live Updates
Myeloma: Isatuximab 4-Drug Regimen Boosts MRD Negativity : comparemela.com
Myeloma: Isatuximab 4-Drug Regimen Boosts MRD Negativity
'This [research] builds on our experience that four-drug combinations with a monoclonal antibody, proteasome inhibitor, immunomodulatory drug, and steroids are superior to three-drug combinations.'
Related Keywords
Boston ,
Massachusetts ,
United States ,
Italy ,
Dana Farber Cancer Institute ,
American ,
Bristol Myers Squibb Celgene ,
Joseph Mikhael ,
Irene Ghobrial ,
Pfizer ,
City Of Hope Cancer Center ,
American Society Of Hematology ,
University Of Torino ,
International Myeloma Foundation ,
Goodyear ,
Glaxosmithkline ,
Division Of Hematology ,
Translational Genomics Research Institute Tgen ,
Health Sciences ,
Department Of Molecular Biotechnology ,
Amgen ,
Translational Genomics Research Institute ,
Hope Cancer Center ,
American Society ,
Francesca Gay ,
Molecular Biotechnology ,
Medical Oncology ,
Bristol Myers ,
Multiple Myeloma ,
Myeloma ,
Plasma Cell Myeloma ,
Biologic Therapy ,
Iologics ,
Monoclonal Antibody ,
Etuximab ,
Ituximab ,
Proteasome Inhibitor ,
Bortezomib ,
Autologous Stem Cell Transplant ,
Autologous Stem Cell Transplantation ,
Dna Sequencing ,
Dna Sequence ,
Rna Sequences ,
Sequencing Dna ,
Next Generation Sequencing ,
Bags ,
Sequencing By Synthesis ,
Jobs ,
Whole Genome Sequencing ,
comparemela.com © 2020. All Rights Reserved.